Multiple studies have demonstrated the memory-enhancing effects of melatonin and its derivatives in animal models. It is also known that the formation of both short- and long-term memories… read more.
AbbVie announced that the European Commission has approved Aquipta (atogepant) for the prophylaxis of migraine in adults who have four or more migraine days per month. The approval… read more.
Astellas Pharma Inc announced the FDA approved Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD) on August 4,… read more.
There is a need to better deliver information on medical nutrition therapy for patients with Parkinson’s disease (PD). Findings of a new study in the Journal of Nutrition Education and Behavior,… read more.
AbbVie has launched Vyalev (foslevodopa + foscarbidopa), a continuous subcutaneous infusion for Parkinson’s disease, in Japan on July 26. This is the first Parkinson’s drug in the country… read more.
The majority of individuals with multiple sclerosis (MS) treat the chronic and progressive neurological disorder with oral medications, likely because of many factors, including convenience, consumer advertising and… read more.
Higher testosterone levels during adolescence are associated with increased involvement of the brain’s anterior prefrontal cortex (aPFC) in emotion control, but the opposite effect occurs during adulthood. In… read more.
The results of a clinical trial have shown that a drug commonly used for patients with bleeding disorders has the potential to be used to lessen the side… read more.
Neurologic illnesses, including Alzheimer’s, brain cancer, amyotrophic lateral sclerosis (ALS) and stroke, are among the most dreaded illnesses in medicine and leading causes of disability and death worldwide…. read more.
AbbVie announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the approval of atogepant for the… read more.
SK Biopharmaceuticals said that Health Canada granted a Notice of Compliance for Xcopri (ingredient: cenobamate), its epilepsy drug, approving its application for marketing authorization in Canada. Paladin Labs,… read more.
Researchers from The University of Texas at El Paso’s School of Pharmacy will explore the viability of a new treatment for vascular dementia, thanks to a $2.2 million… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
